ReviewAAPS PharmSciTech2026
ML-Driven Pharmaceutical Cocrystal Technology: Advances in Screening, Property Prediction and Applications.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recently, pharmaceutical cocrystal technology has garnered considerable global attention because of its innovativeness and environmental sustainability. This technology effectively enhances the bioavailability of poorly soluble drugs and optimizes their physicochemical and biological properties. Considering the pivotal role of cocrystal screening in improving drug bioavailability, herein, we develop a comprehensive framework for understanding the definition, screening, key characteristics, and applications of drug cocrystals in contemporary drug development. We discuss a series of innovative and efficient screening methods, such as high-throughput computational screening, artificial intelligence screening, and Raman spectroscopy, focusing particularly on the application of machine learning (ML) algorithms. Such algorithms can analyze large volumes of physicochemical data for virtual cocrystal screening and solubility prediction. Compared with traditional experimental screening methods-such as X-ray diffraction, thermal analysis (TA), and high-performance liquid chromatography (HPLC), ML models can manage high workload, address gaps in screening, and facilitate accurate solubility prediction. By using ML models, researchers can narrow the experimental scope and accelerate the discovery and development of novel drug cocrystals. This approach holds promise for enhancing drug efficacy, reducing adverse reactions, and improving patient compliance. Future studies should integrate experimental and virtual screening methods to enhance the efficiency and accuracy of cocrystal selection.
Indexed as
Identifiers
41507647What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.